XML 47 R50.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration and License Agreements - Additional Information 1 (Detail) (USD $) | 1 Months Ended | 12 Months Ended | 1 Months Ended
--- | --- | --- | ---
Feb. 28, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | May 31, 2014
License And Collaboration Agreements [Line Items] |  |  |  |
Stock issued during period value, new issues |  | $ 76,716,000 us-gaap_StockIssuedDuringPeriodValueNewIssues | $ 83,623,000 us-gaap_StockIssuedDuringPeriodValueNewIssues |
Stock issued during the period for new issue | 1,800,000 us-gaap_StockIssuedDuringPeriodSharesNewIssues |  |  |
Deferred revenue current |  | 14,248,000 us-gaap_DeferredRevenueCurrent | 20,267,000 us-gaap_DeferredRevenueCurrent |
Deferred revenue non-current |  | 16,472,000 us-gaap_DeferredRevenueNoncurrent | 7,136,000 us-gaap_DeferredRevenueNoncurrent |
Janssen Biotech Inc. [Member] |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |
Collaboration agreement date |  | December 2014 |  |
Stock issued during period value, new issues |  | 75,000,000 us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Stock issued during the period for new issue |  | 1,923,077 us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Common stock price per share |  | $ 39.00 us-gaap_SaleOfStockPricePerShare / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Nonrefundable upfront payment receivable |  | 50,000,000 mgnx_NonRefundableUpfrontPaymentReceivable / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Clinical, regulatory and commercialization milestone payments |  | 575,000,000 mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Recognized revenue under agreement |  | 0 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Deferred revenue |  | 0 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = mgnx_JanssenBiotechIncMember |  |
Takeda [Member] |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |
Collaboration agreement date |  | May 2014 |  |
Recognized revenue under agreement |  | 3,000,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Deferred revenue |  | 7,100,000 us-gaap_DeferredRevenue / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Nonrefundable upfront payment |  |  |  | 15,000,000 mgnx_NonRefundableUpFrontPayment / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember
License option fee and early development milestone |  | 18,000,000 mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Development, regulatory and sales milestone payments |  | 468,500,000 mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Amount allocated to agreement |  | 10,000,000 mgnx_UpfrontFeeAllocatedToAgreement / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Expected period of development |  | 24 months |  |
Deferred revenue current |  | 5,000,000 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Deferred revenue non-current |  | 2,100,000 us-gaap_DeferredRevenueNoncurrent / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember |  |
Takeda [Member] | Research Collaboration And License Option Agreement [Member] |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |
Collaboration agreement date |  | September 2014 |  |
Recognized revenue under agreement |  | 5,000,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember / us-gaap_TypeOfArrangementAxis = mgnx_ResearchCollaborationAndLicenseOptionAgreementMember |  |
Amount allocated to agreement |  | $ 5,000,000 mgnx_UpfrontFeeAllocatedToAgreement / us-gaap_CounterpartyNameAxis = mgnx_TakedaMember / us-gaap_TypeOfArrangementAxis = mgnx_ResearchCollaborationAndLicenseOptionAgreementMember |  |

X
- Definition Additional potential clinical regulatory commercialization payments under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate potential development regulatory and sales milestone payments available to be earned under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration and license agreement entered date. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | us-types:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable up front payment. + References No definition available. + Details
Name: | mgnx_NonRefundableUpFrontPayment
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Initial fee receivable from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontPaymentReceivable
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential license option fee and early development milestone fee. + References No definition available. + Details
Name: | mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Portion of upfront fee allocated to agreement. + References No definition available. + Details
Name: | mgnx_UpfrontFeeAllocatedToAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period over which upfront payment is to be recognized. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_TakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |